{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:12:47Z","timestamp":1780917167030,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T00:00:00Z","timestamp":1795132800000},"content-version":"am","delay-in-days":292,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1U19AI109680-01"],"award-info":[{"award-number":["1U19AI109680-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1U19AI142759-01"],"award-info":[{"award-number":["1U19AI142759-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bmcl.2025.130473","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T22:18:05Z","timestamp":1763590685000},"page":"130473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synthesis of novel 6-azacytidine prodrugs as potent influenza A inhibitors"],"prefix":"10.1016","volume":"131","author":[{"given":"Omar","family":"Moukha-Chafiq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry D.","family":"Bratton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuklendu D.","family":"Karyakarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Keith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohanka","family":"Martinez-Gzegozewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarath C.","family":"Sarngadharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Bostwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish K.","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne E.","family":"Augelli-Szafran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2025.130473_bb0005","unstructured":"WHO. Influenza (seasonal) \u2013 World Health Organization (WHO). 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal) (accessed 18 July 2025)."},{"key":"10.1016\/j.bmcl.2025.130473_bb0010","unstructured":"CDC. Types of Influenza Viruses: Influenza virus basics. Centers for Disease Control and Prevention (CDC). 2024. https:\/\/www.cdc.gov\/flu\/about\/viruses-types.html (accessed 18 July 2025)."},{"key":"10.1016\/j.bmcl.2025.130473_bb0015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cnur.2019.02.009","article-title":"Seasonal Influenza (Flu)","volume":"54","author":"Keilman","year":"2019","journal-title":"Nurs Clin North Am"},{"key":"10.1016\/j.bmcl.2025.130473_bb0020","unstructured":"Tokimatsu I, Nasu M. [Anti-influenza A viral drug--amantadine]. Nihon Rinsho 2000;58:2288\u20132292."},{"key":"10.1016\/j.bmcl.2025.130473_bb0025","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.1021\/jp800171m","article-title":"A secondary gate as a mechanism for inhibition of the M2 proton channel by amantadine","volume":"112","author":"Yi","year":"2008","journal-title":"J Phys Chem B"},{"key":"10.1016\/j.bmcl.2025.130473_bb0030","doi-asserted-by":"crossref","first-page":"11872","DOI":"10.1021\/bi9014488","article-title":"Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza a virus","volume":"48","author":"Balannik","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmcl.2025.130473_bb0035","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3390\/molecules21111513","article-title":"Influenza neuraminidase inhibitors: synthetic approaches, derivatives and biological activity","volume":"21","author":"Laborda","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2025.130473_bb0040","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1080\/14656566.2019.1626824","article-title":"Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives","volume":"20","author":"Bassetti","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bmcl.2025.130473_bb0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2018.07.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017","volume":"15","author":"Lackenby","year":"2018","journal-title":"Antivir Res"},{"key":"10.1016\/j.bmcl.2025.130473_bb0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1345\/aph.10118","article-title":"Neuraminidase inhibitors: zanamivir and oseltamivir","volume":"35","author":"McNicholl","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.bmcl.2025.130473_bb0055","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1056\/NEJM199709253371302","article-title":"Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 influenza study group","volume":"337","author":"Hayden","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2025.130473_bb0060","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/phar.2370","article-title":"Oseltamivir for all: should it become an over-the-counter medication for influenza treatment?","volume":"40","author":"Rech","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bmcl.2025.130473_bb0065","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s40265-018-0981-8","article-title":"Peramivir: a review in uncomplicated influenza","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bmcl.2025.130473_bb0070","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/eri.11.112","article-title":"Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza","volume":"9","author":"Ikematsu","year":"2011","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"10.1016\/j.bmcl.2025.130473_bb0075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antivir Res"},{"key":"10.1016\/j.bmcl.2025.130473_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2025.130473_bb0085","unstructured":"Lane EJ, Fujifilm in Avigan API license with Zhejiang Hisun Pharmaceuticals, 13 June 2016. Fujifilm in Avigan API license with Zhejiang Hisun Pharmaceuticals | Fierce Pharma."},{"key":"10.1016\/j.bmcl.2025.130473_bb0090","first-page":"45","article-title":"A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?","volume":"6","author":"Pilkington","year":"2020","journal-title":"J Vir Erad"},{"key":"10.1016\/j.bmcl.2025.130473_bb0095","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3851\/IMP3212","article-title":"Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a phase IIa, randomized, double-blind, placebo-controlled study","volume":"23","author":"Trevejo","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bmcl.2025.130473_bb0100","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/infdis\/jiy547","article-title":"Phase 2b study of Pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza a: TOPAZ trial","volume":"219","author":"Finberg","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bmcl.2025.130473_bb0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coviro.2019.01.006","article-title":"The new influenza drug on the market","volume":"35","author":"O\u2019Hanlon","year":"2019","journal-title":"Curr Opin Virol"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130473_bb0110","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00766-18","article-title":"Orally efficacious broad-Spectrum Ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses","volume":"62","author":"Yoon","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2025.130473_bb0115","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1081\/NCN-100002508","article-title":"Palchikovskaja l, Povnitsa O, 6-azacytidine - compound with wide spectrum of antiviral activity","volume":"20","author":"Alexeeva","year":"2001","journal-title":"Nucleos Nucleot Nucl"},{"key":"10.1016\/j.bmcl.2025.130473_bb0120","first-page":"75","article-title":"Toxico-pharmacological properties of 6-azacytidine","volume":"50","author":"Petrusha","year":"1987","journal-title":"Farmakol Toksikol"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130473_bb0125","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/15257770.2015.1034363","article-title":"Synthesis and comparative study of anti-adenoviral activity of 6-Azacytidine and its analogues","volume":"34","author":"Alexeeva","year":"2015","journal-title":"Nucleos Nucleot Nucl."},{"key":"10.1016\/j.bmcl.2025.130473_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105591","article-title":"Identification of broad-spectrum neutralizing antibodies against influenza a virus and evaluation of their prophylactic efficacy in mice","volume":"213","author":"Son","year":"2023","journal-title":"Antivir Res"},{"issue":"7","key":"10.1016\/j.bmcl.2025.130473_bb0135","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02149-19","article-title":"Identification and characterization of novel compounds with broad-spectrum antiviral activity against influenza A and B viruses","volume":"94","author":"Park","year":"2020","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130473_bb0140","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0166-3542(02)00013-X","article-title":"Identification of active antiviral compounds against a New York isolate of West Nile virus","volume":"55","author":"Morrey","year":"2002","journal-title":"Antivir Res"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130473_bb0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.antiviral.2003.09.005","article-title":"In vitro inhibition of chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-\u03b1 and ribavirin combination","volume":"61","author":"Briolant","year":"2004","journal-title":"Antivir Res"},{"issue":"16","key":"10.1016\/j.bmcl.2025.130473_bb0150","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1021\/jm060202r","article-title":"Design of Inhibitors of Orotidine monophosphate decarboxylase using Bioisosteric replacement and determination of inhibition kinetics","volume":"49","author":"Poduch","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130473_bb0155","series-title":"Essentials of Medical Biochemistry","first-page":"465","article-title":"Chapter 25 - nucleotide metabolism","author":"Bhagavan","year":"2015"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130473_bb0160","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.slasd.2023.10.008","article-title":"High-throughput cell-based immunofluorescence assays against influenza","volume":"29","author":"Martinez-Gzegozewska","year":"2024","journal-title":"SLAS Discov"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130473_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0706446","article-title":"Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy","volume":"147","author":"De Clercq","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"7","key":"10.1016\/j.bmcl.2025.130473_bb0170","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S0968-0896(00)00087-0","article-title":"The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine","volume":"8","author":"Shimma","year":"2000","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2025.130473_bb0175","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ejmech.2013.09.047","article-title":"Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides","volume":"70","author":"McGuigan","year":"2013","journal-title":"Euro J Med Chem"},{"issue":"18","key":"10.1016\/j.bmcl.2025.130473_bb0180","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.1021\/cr5002035","article-title":"Synthesis of nucleoside phosphate and phosphonate prodrugs","volume":"114","author":"Pradere","year":"2014","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmcl.2025.130473_bb0185","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1021\/acs.jmedchem.7b00734","article-title":"The proTide prodrug technology: from concept to the clinic","volume":"61","author":"Mehellou","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130473_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130349","article-title":"Discovery of a novel non-toxic analog of clofarabine for the treatment of triple\u2013negative breast cancer","volume":"128","author":"Moukha-Chafiq","year":"2025","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2025.130473_bb0195","unstructured":"Moukha-Chafiq O, Pathak AK, Karyakarte SD, Bartton LD, Augelli-Szafran CE, Diamond M, Shi PY, Hirsh AJ, Smith JL, Streblow D, Haese N, Ying N. 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections. WO2022\/133323 A1, USA."},{"key":"10.1016\/j.bmcl.2025.130473_bb0200","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2174\/1389557517666170216151601","article-title":"Amino acid Ester prodrugs of nucleoside and nucleotide antivirals","volume":"17","author":"Krecmerova","year":"2017","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.bmcl.2025.130473_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1173432","article-title":"Advanced prodrug strategies in nucleoside analogues targeting the treatment of gastrointestinal malignancies","volume":"11","author":"Xu","year":"2023","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130473_bb0210","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3390\/pharmaceutics5020261","article-title":"Preclinical absorption, distribution, metabolism, and excretion of an oral amide prodrug of gemcitabine designed to deliver prolonged systemic exposure","volume":"5","author":"Wickremsinhe","year":"2013","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.bmcl.2025.130473_bb0215","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3390\/pharmaceutics12111031","article-title":"Prodrugs for improved drug delivery: lessons learned from recently developed and marketed products","volume":"12","author":"Markovic","year":"2020","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130473_bb0220","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ymthe.2019.11.026","article-title":"The emerging role of cytidine deaminase in human diseases: a new opportunity for therapy?","volume":"28","author":"Frances","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.bmcl.2025.130473_bb0225","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2174\/092986706776360969","article-title":"Carboxylesterases\u2014detoxifying enzymes and targets for drug therapy","volume":"13","author":"Potter","year":"2006","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmcl.2025.130473_bb0230","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1023\/A:1018982505021","article-title":"Intestinal peptide transport systems and oral drug availability","volume":"16","author":"Yang","year":"1999","journal-title":"Pharm Res"},{"key":"10.1016\/j.bmcl.2025.130473_bb0235","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2010.02.001","article-title":"Human and viral nucleoside\/nucleotide kinases involved in antiviral drug activation: structural and catalytic properties","volume":"86","author":"Deville-Bonnea","year":"2010","journal-title":"Antivir Res"},{"key":"10.1016\/j.bmcl.2025.130473_bb0240","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0026-895X(24)12578-3","article-title":"Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases","volume":"5","author":"Rompay An","year":"2001","journal-title":"Mol Pharm"},{"issue":"17","key":"10.1016\/j.bmcl.2025.130473_bb0245","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.drudis.2022.02.013","article-title":"Nucleosides and emerging viruses: a new story","volume":"27","author":"Roy","year":"2022","journal-title":"Drug Discov Today"},{"issue":"12","key":"10.1016\/j.bmcl.2025.130473_bb0250","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1080\/17460441.2021.1961741","article-title":"An update on the importance of plasma protein binding in drag discovery and development","volume":"16","author":"Di","year":"2021","journal-title":"Expert Opin. Drug Discov."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25003828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25003828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:34:42Z","timestamp":1780914882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25003828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":50,"alternative-id":["S0960894X25003828"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130473","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis of novel 6-azacytidine prodrugs as potent influenza A inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130473"}}